Halozyme to Present at the BIOCOM Investor Conference on October 26
October 19 2009 - 8:00AM
PR Newswire (US)
SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Halozyme Therapeutics,
Inc. (NASDAQ:HALO), a biopharmaceutical company developing and
commercializing products targeting the extracellular matrix, today
announced its participation in the BIOCOM Investor Conference to be
held on October 26-27, 2009 in San Diego. Kurt Gustafson, CFO, will
present an overview of Halozyme and its product development
pipeline on Monday, October 26 at 3:00 p.m. PDT (6:00 p.m. EDT). To
listen to the audio webcast of the presentation live or after the
event, please visit the company's Web site at
http://www.halozyme.com/. The replay will be available for 30 days
after the presentation. About Halozyme Therapeutics, Inc. Halozyme
is a biopharmaceutical company developing and commercializing
products targeting the extracellular matrix for the endocrinology,
oncology, dermatology and drug delivery markets. The company's
portfolio of products and product candidates is based on
intellectual property covering the family of human enzymes known as
hyaluronidases and additional enzymes that affect the extracellular
matrix. Halozyme's Enhanze(TM) Technology is a novel drug delivery
platform designed to increase the absorption and dispersion of
biologics. The company has key partnerships with Roche to apply
Enhanze Technology to Roche's biological therapeutic compounds for
up to 13 targets and with Baxter BioScience to apply Enhanze
Technology to Baxter's biological therapeutic compound, GAMMAGARD
LIQUID(TM). The product candidates in Halozyme's research pipeline
target multiple areas of significant unmet medical need. For more
information visit http://www.halozyme.com/. Halozyme Contact Robert
H. Uhl Senior Director, Investor Relations (858) 704-8264
DATASOURCE: Halozyme Therapeutics, Inc. CONTACT: Robert H. Uhl,
Senior Director, Investor Relations of Halozyme, +1-858-704-8264,
Web Site: http://www.halozyme.com/
Copyright